Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of Skyline Therapeutics Limited, a clinical-stage gene therapy developer, excluding its U.S. subsidiary Skyline Therapeutics (US) Inc. The transaction includes a $15 million merger consideration plus up to $43 million in development, sales milestones, sub-license commissions, and single-digit sales royalties.
Transaction Details
The deal grants Amoytop access to Skyline’s adeno-associated virus (AAV) gene therapy platform and pipeline. Key programs include:
- A next-gen SMN gene replacement therapy for spinal muscular atrophy (SMA).
- A liver-targeted gene therapy for Wilson’s disease.
- Ophthalmic gene therapy for hereditary retinopathy.
- Gene therapy for hereditary cardiomyopathy.
Upon closing, Skyline will become a wholly owned subsidiary of Amoytop.
Strategic Implications
The acquisition positions Amoytop to leverage Skyline’s AAV platform, advancing its pipeline in rare genetic diseases. The deal underscores Amoytop’s expansion into gene therapy, complementing its existing biotech portfolio.-Fineline Info & Tech
Leave a Reply